AOLS (Aeolus Pharmaceuticals) Total Stockholders Equity: $0.21 Mil (As of Jun. 2017)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Aeolus Pharmaceuticals Total Stockholders Equity?

Aeolus Pharmaceuticals AOLS Total Stockholders Equity is $0.21 Mil as of Jun. 2017.

Aeolus Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Jun. 2017 was $0.21 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Aeolus Pharmaceuticals's Book Value per Share for the quarter that ended in Jun. 2017 was $0.00. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Aeolus Pharmaceuticals's Debt-to-Equity for the quarter that ended in Jun. 2017 was 0.00.

Aeolus Pharmaceuticals  (OTCPK:AOLS) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Aeolus Pharmaceuticals's Book Value per Share for the quarter that ended in Jun. 2017 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(0.207-0)/152.086
=0.00

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Aeolus Pharmaceuticals's Debt-to-Equity for the quarter that ended in Jun. 2017 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / 0.207
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aeolus Pharmaceuticals Total Stockholders Equity Related Terms

Aeolus Pharmaceuticals Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Aeolus Pharmaceuticals's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aeolus Pharmaceuticals Total Stockholders Equity Chart

Aeolus Pharmaceuticals Annual Data
Trend Sep07 Sep08 Sep09 Sep10 Sep11 Sep12 Sep13 Sep14 Sep15 Sep16
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -20.34 0.71 1.59 -0.85 3.20

Aeolus Pharmaceuticals Quarterly Data
Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.19 3.20 2.14 1.13 0.21
What does a Total Stockholders Equity of $0.21 Mil mean?
Aeolus Pharmaceuticals (AOLS) has a Total Stockholders Equity of $0.21 Mil as of Jun. 2017. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Aeolus Pharmaceuticals and its competitors.
Is Aeolus Pharmaceuticals' Total Stockholders Equity too high?
Aeolus Pharmaceuticals' current Total Stockholders Equity is $0.21 Mil.
How does Aeolus Pharmaceuticals' Total Stockholders Equity compare to RDGL and PCYN?
Aeolus Pharmaceuticals' Total Stockholders Equity of $0.21 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Drug Manufacturers company?
A good Total Stockholders Equity depends on the Drug Manufacturers industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Aeolus Pharmaceuticals and its competitors. Aeolus Pharmaceuticals's current Total Stockholders Equity is $0.21 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aeolus Pharmaceuticals stock overvalued right now?
Aeolus Pharmaceuticals (AOLS) has a current Total Stockholders Equity of $0.21 Mil. The current Total Stockholders Equity is $0.21 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Aeolus Pharmaceuticals (AOLS), the current Total Stockholders Equity is $0.21 Mil as of Jun. 2017. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aeolus Pharmaceuticals Business Description

Address 26361 Crown Valley Parkway, Suite 150, Mission Viejo, CA, USA, 92691
Aeolus Pharmaceuticals Inc is a Southern California-based biopharmaceutical company. The company is developing a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious disease and diseases of the central nervous system. Aeolus is developing its lead compound, AEOL-10150, as a treatment for the lung effects of Acute Radiation Syndrome (Lung-ARS). Aeolus also has two pre-clinical development programs: AEOL 11114 and AEOL 20415.